Introduction/Aim. Anemia is a common extraintestinal manifestation of inflammatory bowel diseases (IBDs). Recognizing and treating anemia in patients with IBD is vital for improving the quality of life and reducing complications. The aim of this study was to assess the effectiveness and safety of the liposomal iron formulation in the treatment of anemia in patients with Crohn's disease and ulcerative colitis. Method. Among 447 patients in the state of clinical remission of ucerative colitis and Crohn's disease treated with biological therapy, there were 37 patients with confirmed sideropenic anemia (Hb 10 g/dl-12 g/l, ferritin less than 100) who received a liposomal iron pyrophosphate preparation at the dose of 30 mg daily for one month. Parameters such as hemoglobin level, hematocrit, ferritin, and mean corpuscular volume (MCV) were monitored, along with anemia symptoms, and correlated with the onset of therapy; quality of life was also assessed. Statistical analysis was performed using the SPSS program. Results. The application of liposomal iron over one month resulted in a statistically significant increase in hemoglobin levels, averaging 3 g/dL (p = 0.021). A significant increase in hemoglobin was observed in patients in endoscopic remission, almost 10 g/dL (p = 0.008). Additionally, there was an average increase in ferritin levels by almost 2 ng/mL (p = 0.514) and hematocrit by 0.006% (p = 0.126), although these increases did not reach statistical significance. Analyzing the results based on the type of IBD, greater efficacy was observed in patients with ulcerative colitis, showing a significant increase in hemoglobin of 8 g/dL (p = 0.012) compared to patients with Crohn's disease. Two patients reported abdominal discomfort and diarrhea (5.4%) as adverse effects. Conclusion. Our results suggest that 8.3% of IBD patients in clinical remission have anemia and liposomal iron is an effective and safe option for treating anemia in patients. Further research is needed to evaluate the long-term effectiveness and safety of liposomal iron in this patient population.
References
1.
KULNIGG S, GASCHE C. Systematic review: managing anaemia in Crohn’s disease. Alimentary Pharmacology & Therapeutics. 2006;24(11–12):1507–23.
2.
Müller H, Schmidt R, Klein A. Meta-analysis of oral iron formulations in inflammatory bowel disease. Ther Adv Gastroenterol. 2024;17:1–10.
3.
García L, Martínez P, Lopez S. Comparative efficacy of liposomal and intravenous iron in IBD patients: A randomized trial. Dig Dis Sci. 2024;69(2):167–75.
4.
Li J, Zhao X, Chen Y. Liposomal iron in the treatment of anemia in IBD: A prospective study. J Clin Gastroenterol. 2023;57(6):345–52.
5.
Brown R, White P. Managing anemia in inflammatory bowel diseases: Innovations in treatment. World J Gastroenterol. 2021;27(12):1420–7.
6.
Jones C, Brown T. Long-term adherence and efficacy of oral iron in IBD patients. Clin Nutr. 2019;38(7):1205–12.
7.
Smith A, Johnson B. Efficacy of liposomal ironpyrophosphate in anemia treatment. J Gastroenterol. 2020;115(3):456–60.
8.
Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis. PLOS ONE. 10(2):e0117383.
9.
Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor- treatment. Haematologica. 2010;95(2):199–205.
10.
Oustamanolakis P, Koutroubakis IE. Anemia of chronic disease/persistent inflammation in inflammatory bowel disease: Pathogenetic insights. World J Gastroenterol. 2011;17(31):3974–85.
11.
Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.
12.
Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010;95(2):175–8.
13.
Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, et al. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn’s and Colitis. 2015;9(3):211–22.
14.
Weiss G, Goodnough LT. Anemia of Chronic Disease. New England Journal of Medicine. 2005;352(10):1011–23.
15.
Lee TW, Kolber MR, Fedorak RN, Zanten SJ. Iron replacement therapy in inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(5):882–92.
16.
Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–16.
17.
Organization WH. Nutritional anaemias: Tools for effective prevention and control. 2017.
18.
Gasche C, Lomer MCE, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190–7.
19.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology. 2015;12(12):720–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
